DOST to lead clinical trials for Moscow vaccine

The Department of Science and Technology will lead the clinical trials for a COVID-19 vaccine developed and offered to the Philippines by Russia.

The Department of Health said the clinical trials will be done in accordance with the requirements of the Food and Drug Administration.

The department, however, did not give a number yet as to the volunteer subjects for the clinical trial.

The Russian Direct Investment Fund has proposed to establish a partnership with the Philippines to conduct clinical trials, supply doses of COVID-19 vaccine, and set-up local manufacturing.

On Monday, President Rodrigo Duterte accepted Russia's offer and even volunteered to be the first test subject.

The Russian Federation has completed Phase 3 of clinical trials on the vaccine developed by the National Research Center for Epidemiology, according to the DOH.

On Tuesday, Russian President Vladimir Putin said the vaccine trials have yielded positive results, with all volunteers having built up immunity to the coronavirus.

The vaccine is based on adenovirus and contains dead COVID-19 particles that cannot multiply and are therefore safe, said Alexander Gintzburg, head of the center.

Earlier, the World Health Organization warned Russia that "it should not stray from the usual methods of testing a vaccine for safety and effectiveness."

In the latest WHO's list of vaccine trials globally, the Russian phase of the COVID-19 vaccine clinical trials is not included. 

Topics: Vaccine , Russia , DOST , DOH , COVID-19 , Coronavirus
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.